Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer.
- DOI
- 10.1016/j.esmogo.2026.100324
- Published
- 2026 Jun
- Container
- ESMO gastrointestinal oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.esmogo.2026.100324,
title = {Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer.},
author = {Fakih M and Gill S and Sampat K and Chan DL and Fisher G and Cruz-Correa M and Lenz HJ and Garcia-Alfonso P and Forget F and Lonardi S and Krauss J and Chen E and Cubillo Gracian A and Liu Y and van Buuren N and Shao J and Dong M and Chen A and Tejani M and Hecht JR},
year = {2026},
journal = {ESMO gastrointestinal oncology},
doi = {10.1016/j.esmogo.2026.100324},
url = {https://doi.org/10.1016/j.esmogo.2026.100324}
}RIS
TY - JOUR TI - Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer. AU - Fakih M AU - Gill S AU - Sampat K AU - Chan DL AU - Fisher G AU - Cruz-Correa M AU - Lenz HJ AU - Garcia-Alfonso P AU - Forget F AU - Lonardi S AU - Krauss J AU - Chen E AU - Cubillo Gracian A AU - Liu Y AU - van Buuren N AU - Shao J AU - Dong M AU - Chen A AU - Tejani M AU - Hecht JR PY - 2026 JO - ESMO gastrointestinal oncology DO - 10.1016/j.esmogo.2026.100324 UR - https://doi.org/10.1016/j.esmogo.2026.100324 ER -
APA
M, F., S, G., K, S., DL, C., G, F., M, C., HJ, L., P, G., F, F., S, L., J, K., E, C., A, C. G., Y, L., N, V. B., J, S., M, D., A, C., M, T., & JR, H. (2026). Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer.. ESMO gastrointestinal oncology. https://doi.org/10.1016/j.esmogo.2026.100324
Source records
- pubmed · retrieved 2026-09-26T06:31:00.988Z